Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2026
Amneal Pharmaceuticals completes acquisition of Kashiv BioSciences
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences for up to $1.1 billion, creating a fully integrated global biosimilars platform. Terms included $375 million in cash, $375 million in equity at closing, and up to $350 million in additional milestone and contingent payments.
2020
Amneal announces increased hydroxychloroquine production
Amneal Pharmaceuticals announced that it was ramping up hydroxychloroquine sulphate production at several manufacturing sites and expected to produce approximately 20 million tablets by mid-April.
2019
Amneal recalls ranitidine products over potential NDMA impurity
Amneal Pharmaceuticals issued a voluntary consumer-level recall of specified ranitidine tablets and syrup because they could contain NDMA amounts above levels established by the FDA. The article reports no confirmed adverse events directly related to the recall.